Methocarbamol

Identification

Summary

Methocarbamol is a CNS depressant indicated with rest, physical therapy and other treatments to control the discomfort associated with various acute musculoskeletal conditions.

Brand Names

Robaxacet, Robaxacet-8, Robaxin, Robaxisal

Generic Name

Methocarbamol

DrugBank Accession Number

DB00423

Background

Methocarbamol was developed in the early 1950s as a treatment for muscle spasticity and the associated pain.^6,7 It is a guaiacol glyceryl ether.⁷

Methocarbamol tablets and intramuscular injections are prescription medicines indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.^Label,9 In Canada, methocarbamol can be sold as an over the counter oral medicine at a lower dose that may be combined with acetaminophen or ibuprofen.¹⁰ A combination product with acetylsalicylic acid and codeine is available in Canada by prescription.¹⁰

Methocarbamol was FDA approved on 16 July 1957.⁸

Type

Small Molecule

Groups

Approved, Vet approved

Structure

Similar Structures

Weight: Average: 241.2405
Monoisotopic: 241.095022595
Chemical Formula: C₁₁H₁₅NO₅

Synonyms

(RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
Methocarbamol
Méthocarbamol
Methocarbamolum
Metocarbamol
Metocarbamolo

Pharmacology

Indication

Methocarbamol tablets and intramuscular injections are indicated in the United States as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.^Label,9 Oral methocarbamol in America may be given up to 1500mg 4 times daily for 2-3 days.³

In Canada, methocarbamol containing oral formulations are sold over the counter for pain associated with muscle spasm.¹⁰ However, if these combination formulations include codeine, they are prescription only.¹⁰

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Contraindications & Blackbox Warnings

Avoid life-threatening adverse drug events

Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events & improve clinical decision support.

Learn more

Pharmacodynamics

Methacarbamol is a skeletal muscle relaxant with an unknown mechanism of action.⁵ Methacarbamol has been shown to block spinal polysynaptic reflexes, decrease nerve transmission in spinal and supraspinal polysynaptic pathways, and prolong the refractory period of muscle cells.^5,4 Methocarbamol does not act as a local anesthetic upon injection.⁴ In animal studies, methocarbamol also prevents convulsions after electric shock.⁵

Mechanism of action

The mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity.³ This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells.^5,4 Methocarbamol has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres.⁹

Target	Actions	Organism
NCarbonic anhydrase 1	inhibitor	Humans

Absorption

The time to maximum concentration is 1.1 hours for both healthy patients and those on hemodialysis.¹ The maximum plasma concentration is 21.3mg/L for healthy patients and 28.7mg/L in hemodialysis patients.¹ The area under the curve for healthy patients is 52.5mg/L*hr and 87.1mg/L*hr in hemodialysis patients.¹ AUC% based on terminal elimination half life is 2% for healthy patients and 4% for hemodialysis patients.¹

Older studies report maximum plasma concentrations in 0.5 hours.²

Volume of distribution

Volume of distribution data in humans is scarce. In horses, the volume of distribution is 515-942mL/kg at steady state or 724-1130mL/kg.⁵

Protein binding

Methocarbamol is 46-50% protein bound in healthy patients and 47.3-48.9% protein bound in hemodialysis patients.¹

Metabolism

Methocarbamol is metabolized in the liver by demethylation to 3-(2-hydroxyphenoxy)-1,2-propanediol-1-carbamate or hydroxylation to 3-(4-hydroxy-2-methoxyphenoxy)-1,2-propanediol-1-carbamate.² Methocarbamol and its metabolites are conjugated through glucuronidation or sulfation.²

Hover over products below to view reaction partners

Methocarbamol
- 3-(2-hydroxyphenoxy)-1,2-propanediol-1-carbamate
- 3-(4-hydroxy-2-methoxyphenoxy)-1,2-propanediol-1-carbamate

Route of elimination

In humans the majority of the dose is eliminated in the urine.² In dogs, 88.85% of the dose is eliminated in urine and 2.14% in the feces.² In rats, 84.5-92.5% of the dose is eliminated in the urine and 0-13.3% is eliminated in the feces.²

Half-life

The elimination half life is 1.14 hours in healthy subjects and 1.24 hours in subjects with renal insufficiency.¹ Older studies report half lives of 1.6-2.15 hours.²

Clearance

0.2-0.8L/h/kg.⁹

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

Learn more

Improve decision support & research outcomes with our structured adverse effects data.

Learn more

Toxicity

Overdose of methocarbamol may be associated with alcohol and other central nervous system depressants.^Label Patients may experience nausea, drowsiness, blurred vision, hypotension, seizures, and coma.^Label Treatment of overdose is generally through airway maintenance, monitoring urinary output, vital signs, and giving fluid intravenously if necessary.^Label

The oral LD50 in rats is 3576.2mg/kg.¹⁰

The FDA has classified methocarbamol as pregnancy category C.^Label Animal and human studies have not been performed to determine the risks to a fetus, however fetal and congenital abnormalities have been reported.^Label Methocarbamol is excreted in the milk of dogs, however it is unknown if this is also the case for humans.^Label Caution should be exercised when taking methocarbamol while breastfeeding.^Label

Studies to assess the carcinogenicity, mutagenicity, or effects on fertility of methocarbamol have not been performed.^Label

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when Methocarbamol is combined with 1,2-Benzodiazepine.
Acetazolamide	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Acetazolamide.
Acetophenazine	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Acetophenazine.
Agomelatine	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Agomelatine.
Alfentanil	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Alfentanil.
Alimemazine	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Alimemazine.
Almotriptan	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Almotriptan.
Alosetron	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Alosetron.
Alprazolam	The risk or severity of CNS depression can be increased when Alprazolam is combined with Methocarbamol.
Alverine	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Alverine.

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Food Interactions

Avoid alcohol.
Take with or without food. The absorption is unaffected by food.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Images

International/Other Brands

Bolaxin (Ying Yuan) / Carbaflex (Paill) / Delaxin / DoloVisan (Dr.Kade Pharmaceutische Fabrik) / Fubaxin (Grape King) / Lumirelax (Juvise) / Metocarbamol (AZ Pharma) / Mioflex (Labinco) / Miorel (Cheminter) / Musxan (Pharmasant) / Ortoton (Recordati) / Rebamol (Winston) / Robaxin-750 (Pfizer) / Robinax (Khandelwal) / Sinaxar (Armofar) / Taspan (Honten)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Methocarb 500-EZS	Kit	500 mg/1	Oral	PureTek Corporation	2018-10-23	Not applicable
Methocarbamol	Tablet	750 mg/1	Oral	Lannett Company, Inc.	2007-06-19	Not applicable
Methocarbamol	Tablet	750 mg/1	Oral	Vintage Pharmaceuticals, LLC	2007-09-13	2007-09-13
Methocarbamol	Tablet	500 mg/1	Oral	Lannett Company, Inc.	2007-06-19	Not applicable
Methocarbamol	Tablet	500 mg/1	Oral	Vintage Pharmaceuticals, LLC	2007-09-13	2007-09-13
Methocarbamol Inj 100mg/ml	Liquid	100 mg / mL	Intramuscular; Intravenous	Univet Pharmaceuticals Ltd.	1988-12-31	Not applicable
Methocarbamol Omega	Liquid	100 mg / mL	Intramuscular; Intravenous	Omega Laboratories Ltd	2003-07-28	Not applicable
Robaximol Inj 100mg/ml	Liquid	100 mg / mL	Intramuscular; Intravenous	Montreal Veterinary Products Inc.	1989-12-31	2021-06-14
Robaxin	Tablet	500 mg/1	Oral	Remedy Repack	2012-07-23	2013-07-24
Robaxin	Tablet, film coated	750 mg/1	Oral	Ucb Inc	2003-01-20	2014-10-31

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Methcarbamol	Tablet	500 mg/1	Oral	Central Packaging	2013-03-20	Not applicable
Methocarbamol	Tablet	500 mg/1	Oral	Cardinal Health	2007-07-03	Not applicable
Methocarbamol	Tablet, coated	500 mg/1	Oral	Direct_Rx	2019-08-27	Not applicable
Methocarbamol	Tablet	750 mg/1	Oral	Preferred Pharmaceuticals, Inc.	2014-11-25	Not applicable
Methocarbamol	Tablet, coated	500 mg/1	Oral	Denton Pharma, Inc. Dba Northwind Pharmaceuticals	2018-07-31	Not applicable
Methocarbamol	Tablet	750 mg/1	Oral	Direct Rx	2016-03-22	Not applicable
Methocarbamol	Tablet	500 mg/1	Oral	REMEDYREPACK INC.	2017-05-19	Not applicable
Methocarbamol	Tablet	750 mg/1	Oral	American Health Packaging	2020-03-25	Not applicable
Methocarbamol	Tablet	750 mg/1	Oral	Preferred Pharmaceuticals, Inc.	2010-08-06	2019-10-28
Methocarbamol	Tablet, film coated	500 mg/1	Oral	A-S Medication Solutions	2015-07-13	2019-11-30

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Robaxin	Tablet	500 mg	Oral	Glaxosmithkline Consumer Healthcare Ulc	1958-12-31	Not applicable
Robaxin 750	Tablet	750 mg	Oral	Glaxosmithkline Consumer Healthcare Ulc	1993-12-31	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
A.S.A. With Methocarbamol Night-time Extra Strength	Methocarbamol (400 mg) + Acetylsalicylic acid (500 mg)	Tablet	Oral	Cellchem Pharmaceuticals Inc.	Not applicable	Not applicable
Acetaminophen 325mg + Methocarbamol 400mg Caplets	Methocarbamol (400 mg) + Acetaminophen (325 mg)	Tablet	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable
Acetaminophen 500mg + Methocarbamol 400mg Extra Strength Caplets	Methocarbamol (400 mg) + Acetaminophen (500 mg)	Tablet	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable
Advil Back Pain	Methocarbamol (500 mg) + Ibuprofen (200 mg)	Tablet	Oral	Glaxosmithkline Consumer Healthcare Ulc	Not applicable	Not applicable
Analgesic and Muscle Relaxant	Methocarbamol (500 mg) + Ibuprofen (400 mg)	Tablet	Oral	Pharmascience Inc	2012-03-20	Not applicable
Analgesic and Muscle Relaxant Caplets	Methocarbamol (500 mg) + Ibuprofen (200 mg)	Tablet	Oral	TEVA Canada Limited	2009-11-18	2021-08-12
Aspirin Backache	Methocarbamol (400 mg) + Acetylsalicylic acid (325 mg)	Tablet	Oral	Bayer	Not applicable	Not applicable
Aspirin Night-time	Methocarbamol (400 mg) + Acetylsalicylic acid (500 mg)	Tablet	Oral	Bayer Inc Consumer Care	2006-05-24	2010-08-05
Axacet-C1/8	Methocarbamol (400 mg) + Acetaminophen (325 mg) + Codeine phosphate (8 mg)	Tablet	Oral	Technilab Pharma Inc.	Not applicable	Not applicable
Axisal-C1/8	Methocarbamol (400 mg) + Acetylsalicylic acid (325 mg) + Codeine phosphate (8 mg)	Tablet	Oral	Technilab Pharma Inc.	Not applicable	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Methocarb 500-EZS	Methocarbamol (500 mg/1)	Kit	Oral	PureTek Corporation	2018-10-23	Not applicable

Chemical Identifiers

UNII: 125OD7737X
CAS number: 532-03-6
InChI Key: GNXFOGHNGIVQEH-UHFFFAOYSA-N
InChI: InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)
IUPAC Name: 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
SMILES: COC1=C(OCC(O)COC(N)=O)C=CC=C1

References

General References

Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G: Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. [Article]
Bruce RB, Turnbull LB, Newman JH: Metabolism of methocarbamol in the rat, dog, and human. J Pharm Sci. 1971 Jan;60(1):104-6. [Article]
Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, Valaer C: Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. P T. 2014 Jun;39(6):427-35. [Article]
Crankshaw DP, Raper C: Mephenesin, methocarbamol, chlordiazepoxide and diazepam: actions on spinal reflexes and ventral root potentials. Br J Pharmacol. 1970 Jan;38(1):148-56. doi: 10.1111/j.1476-5381.1970.tb10343.x. [Article]
Muir WW 3rd, Sams RA, Ashcraft S: The pharmacology and pharmacokinetics of high-dose methocarbamol in horses. Equine Vet J Suppl. 1992 Feb;(11):41-4. [Article]
Authors unspecified: Methocarbamol-A New Lissive Agent. Can Med Assoc J. 1958 Dec 15;79(12):1008-9. [Article]
O'DOHERTY DS, SHIELDS CD: Methocarbamol; new agent in treatment of neurological and neuromuscular diseases. J Am Med Assoc. 1958 May 10;167(2):160-3. [Article]
FDA Approved Drug Products: Robaxin [Link]
FDA Approved Drug Products: Robaxin Intramuscular Injection [Link]
Pfizer Canada: Robax [Link]

External Links

Human Metabolome Database: HMDB0014567
KEGG Drug: D00402
PubChem Compound: 4107
PubChem Substance: 46507761
ChemSpider: 3964
BindingDB: 50239995
RxNav: 6845
ChEBI: 77498
ChEMBL: CHEMBL1201117
PharmGKB: PA164749506
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
PDRhealth: PDRhealth Drug Page
Wikipedia: Methocarbamol

FDA label

Download (121 KB)

MSDS

Download (78.8 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Back Pain Lower Back	1
4	Completed	Treatment	Rib Fractures / Wounds and Injuries	1
4	Recruiting	Treatment	Hip Arthroscopy	1
4	Recruiting	Treatment	Inguinal Hernias / Ventral Hernias	1
4	Suspended	Treatment	Back Pain Lower Back	1
3	Completed	Treatment	Pain	1
3	Recruiting	Treatment	Postoperative pain	1
3	Unknown Status	Treatment	Cirrhosis of the Liver	1
Not Available	Recruiting	Treatment	Kidney Diseases / Kidney Stones / Ureteral Calculus / Ureteral Diseases / Urolithiasis	1

Pharmacoeconomics

Manufacturers

Marsam pharmaceuticals llc
Watson laboratories inc
Baxter healthcare corp anesthesia critical care
Ferndale laboratories inc
Forest laboratories inc
Able laboratories inc
American therapeutics inc
Ascot hosp pharmaceuticals inc div travenol laboratories inc
Clonmel healthcare ltd
Heather drug co inc
Hetero drugs ltd
Impax laboratories inc
Inwood laboratories inc sub forest laboratories inc
Ivax pharmaceuticals inc sub teva pharmaceuticals usa
Kv pharmaceutical co
Lannett co inc
Mutual pharmaceutical co inc
Mylan pharmaceuticals inc
Nylos trading co inc
Pharmeral inc
Pioneer pharmaceuticals inc
Purepac pharmaceutical co
Roxane laboratories inc
Sandoz inc
Solco healthcare us llc
Solvay pharmaceuticals
Superpharm corp
Tablicaps inc
Upsher smith laboratories inc
Vintage pharmaceuticals inc
West ward pharmaceutical corp
Schwarz pharma inc

Packagers

Aidarex Pharmacuticals LLC
Amerisource Health Services Corp.
Amneal Pharmaceuticals
Apical Pharmaceutical Corporation
Apotheca Inc.
A-S Medication Solutions LLC
Baxter International Inc.
Blenheim Pharmacal
Bryant Ranch Prepack
C.O. Truxton Inc.
Cardinal Health
Caremark LLC
Carlisle Laboratories Inc.
Comprehensive Consultant Services Inc.
Corepharma LLC
Coupler Enterprises Inc.
Direct Dispensing Inc.
DispenseXpress Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Group Health Cooperative
H and H Laboratories
H.J. Harkins Co. Inc.
Heartland Repack Services LLC
Hetero Drugs Ltd.
Innoviant Pharmacy Inc.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Keltman Pharmaceuticals Inc.
Lake Erie Medical and Surgical Supply
Lannett Co. Inc.
Liberty Pharmaceuticals
Major Pharmaceuticals
Marisol Corp.
Martin Surgical Supply
Mckesson Corp.
Medisca Inc.
Merit Pharmaceuticals
Murfreesboro Pharmaceutical Nursing Supply
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
Patient First Corp.
PCA LLC
PD-Rx Pharmaceuticals Inc.
Pharmaceutical Utilization Management Program VA Inc.
Pharmacy Service Center
Pharmedix
Pharmpak Inc.
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Qualitest
Rebel Distributors Corp.
Redpharm Drug
Remedy Repack
Resource Optimization and Innovation LLC
Sandoz
Schein Pharmaceutical Inc.
Schwarz Pharma Inc.
Southwood Pharmaceuticals
St Mary's Medical Park Pharmacy
Stat Rx Usa
Talbert Medical Management Corp.
United Research Laboratories Inc.
Va Cmop Dallas
Vangard Labs Inc.
Vintage Pharmaceuticals Inc.
Watson Pharmaceuticals
West-Ward Pharmaceuticals

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral
Tablet, coated	Oral
Tablet	Oral	200 mg
Kit	Oral	500 mg/1
Injection	Intramuscular; Intravenous	100 mg/1mL
Injection	Parenteral	100 mg/1mL
Injection, solution	Intramuscular; Intravenous	1000 mg/10mL
Powder	Not applicable	1 kg/1kg
Tablet	Oral	500 mg/1
Tablet	Oral	750 mg/1
Tablet, coated	Oral	1000 mg/1
Tablet, coated	Oral	500 mg/1
Tablet, coated	Oral	750 mg/1
Tablet	Oral
Powder	Not applicable	90 mg/1001
Solution	Intramuscular; Intravenous	0.1 g
Solution	Parenteral	500 mg
Tablet, delayed release	Oral	750 mg
Solution	Intramuscular; Intravenous	1 g
Tablet, coated	Oral	750 mg
Tablet	Oral	750 mg
Tablet, film coated	Oral	750 mg
Injection, solution	Intramuscular; Intravenous	100 mg/1mL
Tablet, film coated	Oral	500 mg/1
Tablet, film coated	Oral	750 mg/1
Solution	Parenteral	1 g
Liquid	Intramuscular; Intravenous	100 mg / mL
Tablet	Oral	500 mg

Prices

Unit description	Cost	Unit
Robaxin-750 750 mg tablet	2.48USD	tablet
Robaxin 100 mg/ml vial	2.2USD	ml
Robaxin-750 tablet	1.99USD	tablet
Robaxin 500 mg tablet	1.68USD	tablet
Methocarbamol powder	0.95USD	g
Methocarbamol 750 mg tablet	0.49USD	tablet
Methocarbamol 500 mg tablet	0.38USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	92	MSDS
water solubility	2.5g/100mL	MSDS
logP	0.61	CHEM INSPECT TEST INST (1992)

Predicted Properties

Property	Value	Source
Water Solubility	4.21 mg/mL	ALOGPS
logP	0.63	ALOGPS
logP	0.45	Chemaxon
logS	-1.8	ALOGPS
pKa (Strongest Acidic)	13.6	Chemaxon
pKa (Strongest Basic)	-3.4	Chemaxon
Physiological Charge	0	Chemaxon
Hydrogen Acceptor Count	4	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	91.01 Å²	Chemaxon
Rotatable Bond Count	7	Chemaxon
Refractivity	59.07 m³·mol^-1	Chemaxon
Polarizability	24.28 Å³	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9638
Blood Brain Barrier	+	0.5747
Caco-2 permeable	-	0.6689
P-glycoprotein substrate	Non-substrate	0.6452
P-glycoprotein inhibitor I	Non-inhibitor	0.9411
P-glycoprotein inhibitor II	Non-inhibitor	0.8887
Renal organic cation transporter	Non-inhibitor	0.9105
CYP450 2C9 substrate	Non-substrate	0.8431
CYP450 2D6 substrate	Non-substrate	0.7658
CYP450 3A4 substrate	Non-substrate	0.606
CYP450 1A2 substrate	Inhibitor	0.9107
CYP450 2C9 inhibitor	Non-inhibitor	0.9302
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9066
CYP450 3A4 inhibitor	Non-inhibitor	0.9338
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9542
Ames test	Non AMES toxic	0.5776
Carcinogenicity	Non-carcinogens	0.9406
Biodegradation	Not ready biodegradable	0.8358
Rat acute toxicity	2.2930 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.984
hERG inhibition (predictor II)	Non-inhibitor	0.9411

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - , positive	LC-MS/MS	splash10-02t9-0900000000-97aeacf66e8410c23139
MS/MS Spectrum - , positive	LC-MS/MS	splash10-02t9-2900000000-df41a784aa756b8e064d

Targets

Build, predict & validate machine-learning models

Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.

Learn more

Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.

Learn more

Details1. Carbonic anhydrase 1

Kind: Protein
Organism: Humans
Pharmacological action: No
Actions: Inhibitor

General Function: Zinc ion binding
Specific Function: Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name: CA1
Uniprot ID: P00915
Uniprot Name: Carbonic anhydrase 1
Molecular Weight: 28870.0 Da

References

Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 02, 2023 16:39

Methocarbamol

Identification

Structure for Methocarbamol (DB00423)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Targets

References